A Phase 2 Study of HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma


Full Title

Phase 2 Trial of G207 + 5 Gy Radiation for Children with High-Grade Gliomas (PBTC-061) (CIRB)


In this study, researchers are assessing a drug called G207 given with a single radiation dose to treat glioma. The people in this study are children with high-grade glioma that keeps growing or came back after treatment.

G207 is a herpes simplex virus (cold sore virus) that was genetically modified to ensure that it only infects and kills glioma cells without harming normal brain tissue.

If your child joins this study, they will have G207 injected directly into the tumor. They will then receive a single dose of radiation to the tumor within 24 hours of getting G207.

Who Can Join

To join this study, there are a few conditions. Your child must:

  • Have high-grade glioma that came back or keeps growing after initial treatment.
  • Have glioma that is at least 1 cm in size and accessible through surgery.
  • Have recovered from prior surgery and radiation therapy.
  • Have completed previous chemotherapy at least 3 weeks before getting G207.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 3-21.


For more information or to see if your child can join this study, please call 833-MSK-KIDS.




Phase II (phase 2)

Disease Status

Relapsed or Refractory


ClinicalTrials.gov ID